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Since the functional role(s) of angiotensin II (Ang II) type II receptor (AT2R) in type I diabetes is unknown, we hypothesized that
AT2R is involved in decreasing the eﬀects of type I diabetes on the kidneys. We induced diabetes with low-dose streptozotocin
( S T Z )i nb o t hA T 2Rk n o c k o u t( A T 2RKO) and wild-type (WT) male mice aged 12 weeks and followed them for 4 weeks. Three
subgroups nondiabetic, diabetic, and insulin-treated diabetic (Rx insulin implant) were studied. Systolic blood pressure (SBP),
physiological parameters, glomerular ﬁltration rate (GFR), renal morphology, gene expression, and apoptosis were assessed. After
4 weeks of diabetes, compared to WT controls, AT2RKO mice clearly developed features of early diabetic nephropathy (DN), such
as renal hypertrophy, tubular apoptosis, and progressive extracellular matrix (ECM) protein accumulation as well as increased
GFR. AT2RKO mice presented hypertension unaﬀected by diabetes. Renal oxidative stress (measured as heme oxygenase 1 (HO-
1) gene expression and reactive oxygen species (ROS) generation) and intrarenal renin angiotensin system components, such as
angiotensinogen (Agt), AT1R, and angiotensin-converting enzyme (ACE) gene expression, were augmented whereas angiotensin-
converting enzyme2 (ACE2) gene expression was decreased in renal proximal tubules (RPTs) of AT2RKO mice. The renal changes
noted above were signiﬁcantly enhanced in diabetic AT2RKO mice but partially attenuated in insulin-treated diabetic WT and
AT2RKO mice. In conclusion, AT2R deﬁciency accelerates the development of DN, which appears to be mediated, at least in part,
via heightened oxidative stress and ACE/ACE2 ratio in RPTs.
1.Introduction
Diabetic nephropathy (DN) is the single major cause of end-
stage renal failure in North America [1, 2]. Among the mul-
tiple risk factors contributing to diabetic renal disease, the
renin-angiotensin system (RAS), a coordinated hormonal
cascade that has major physiological and pathological eﬀects
on the cardiovascular and renal functions, is one of the
most important systems aﬀecting DN development and pro-
gression [3–5].
Although chronic treatment with RAS blockers is eﬀec-
tive in controlling hypertension and retarding DN progres-
sion, it is not a cure, indicating that the mechanisms of
renal protection by RAS blockers in diabetes are far from
being completely understood, and the discovery of addi-
tional therapeutic pathways as potential drug targets is of
paramount importance [2, 6].
Intrarenal angiotensin II (Ang II), a principal eﬀector
of the RAS that is increased in DN, acts through 2 major
angiotensin receptors, Ang II type I receptor (AT1R) and
AT2R, and may be involved in dysfunctional responses in the
diabetic kidney [3–5]. For instance, Ang II eﬀects within the
kidneyaremediatedbyAT1Randincludecellulardediﬀeren-
tiation and proliferation, renal hypertrophy and apoptosis,
vasoconstriction and heightened renal and tubular sodium
resorption. In contrast to the well-established functional2 Experimental Diabetes Research
impact of AT1R in DN, the functional role of AT2R in the
development of nephropathy in type I diabetes is incom-
pletely understood. AT2R activation appears to suppress
renin biosynthesis and release from renal juxtaglomerular
cells, leading to vasodilatation and natriuresis, both of which
may reduce blood pressure (BP) [3–5].
In the kidneys, AT2R expression in both embryonic and
mature stages (i.e., glomerular endothelial cells, podocytes,
tubular epithelial cells, and inner medullary collecting ducts)
is known and well deﬁned [7]. AT2R-deﬁcient mice (i.e.,
AT2R knockout, AT2RKO) display a phenotype similar to
that of humans with congenital renal and urinary tract
anomalies [8, 9] and incur hypertension in adulthood [8].
These phenotypes highlight the importance of AT2Ri n
normal kidney development and BP regulation, but under-
standing how AT2R is regulated remains elusive.
An additional component of the RAS family, angiot-
ensin-converting enzyme2 (ACE2) [10, 11], shares 42% ho-
mology with angiotensin-converting enzyme (ACE) but has
diﬀerentbiochemicalactivities.ACE2speciﬁcallycleavesAng
I and Ang II into Ang 1-9 and Ang 1-7, respectively. Since
ACE2 and ACE are coexpressed in many tissues, and ACE2
expression is both cardio- and renoprotective, acting in a
counterregulatory manner to ACE in both experimental
animals and humans, alterations in their activities and
the ACE/ACE2 ratio may participate in hypertension and
renal disease [12–14]. Whether AT2R and ACE2 interact in
diabetes, including DN, is unknown. However, since AT2R
inhibits ACE activity [15], we speculated that AT2Ri n
diabetes might lead to heightened ACE2 activity and then to
an increased ACE2/ACE ratio, which could be important in
vasodilatation and natriuresis in DN.
In the current in vivo study, we examined the potential
functional role(s) of AT2R deﬁciency in nephropathy de-
velopment in type I diabetes. We hypothesized that AT2R
deﬁciency will accelerate the progression of DN in type I
diabetes via reactive oxygen species (ROS) generation and
upregulation classic intrarenal RAS gene expression with
downregulation of ACE2 gene expression in renal proximal
tubules (RPTs).
2. Methods
2.1. Animals. Male wild-type (WT, C57/BL6) and AT2RKO
mice (C57/BL6 background, obtained from Dr. Tadashi Ina-
gami, Department of Biochemistry, Vanderbilt University
School of Medicine, Nashville, Tenn, USA) [8] were studied
in vivo.
As described previously [16–18], we induced diabetes in
male AT2RKO and WT mice at the age of 12 weeks with
intraperitoneal multiple injections of streptozotocin (STZ,
Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) at a low-
dose level of ∼45–50mg per kg body weight (BW) daily for
5 consecutive days. Three subgroups (nondiabetic (control),
diabetic, and diabetic treated with insulin implants (LinShin
Canada, Inc., Toronto, ON, Canada)) were sacriﬁced at the
age of 17 weeks after a 4-week experimental period.
Animal care in these experiments met the standards set
forth by the Canadian Council on Animal Care, and all
procedures were approved by the Institutional Animal
Care Committee of the CRCHUM. All AT2RKO and WT
(C57/BL6) mice were housed under standard conditions of
humidity and lighting (12-hour light-dark cycles), with free
access to standard mouse chow and water ad libitum.
2.2. Physiological Studies. B l o o dg l u c o s el e v e l sw e r em e a -
sured with a Side-Kick Glucose Analyzer (Model 1500,
Interscience, ON, Canada) after a 4-hour fast in the morning
as reported previously [16–18]. Mean systolic blood pressure
(SBP) was monitored by the tail-cuﬀ method with the
Visitech BP-2000 Blood Pressure Analysis System for mice
(Visitech System Inc., Apex, NC, USA) as reported elsewhere
[16–18].Brieﬂy,allanimalswereconditionedandacclimated
for 2 weeks (20–30min of SBP measurements per session,
thrice weekly) starting at 10 weeks of age, and then SBP
was measured thrice weekly and averaged per week from 12
weeks of age until 16-weeks of age. Since the animals were
acclimated to BP measurement, we judged that the stress of
having SBP recorded by tail cuﬀ was relatively minimized.
While the technique of tail-cuﬀ measurement is generally
considered less sensitive than telemetry, we believe that our
SBP data is valid and convincing, based on the substantial
numbers of animals used and the longitudinal studies.
A l la n i m a l sw e r ee u t h a n i z e da t1 7w e e k so fa g eu n d e r
CO2 and the kidneys removed immediately. Body weight
(BW) and kidney weight (KW) were rapidly recorded. The
left kidney was utilized for renal morphology and immuno-
histochemistry (IHC). The right kidney was reserved for
renal proximal tubule (RPTs) isolation by the Percoll gra-
dient method as well as for gene expression experiments as
previously reported [16–18].
2.3. Glomerular Filtration Rate (GFR) Measurement. We
estimated the GFR in 16 weeks old animals according to
the protocol described by Qi et al. [19]a n da sr e c o m -
mended by AMDCC (http://www.diacomp.org/). In brief,
each mouse received a single intravenous bolus of 5% ﬂu-
orescein isothiocyanate-inulin (FITC-inulin), after which
7 blood samples (each ∼20μL) were collected from the
saphenous vein at 3, 7, 10, 15, 35, 55, and 75min post-
FITC-inulin injection. Plasma ﬂuorescence concentration at
each time point was measured by Fluoroscan Ascent FL
(Labsystems, Helsinki, Finland) with 485nm excitation and
read at 538nm emission. The GFR was calculated according
to the equation: GFR = I/(A/α + B/β), where I was the
amount of FITC-inulin bolus delivered, A and α were the
y intercept and decay constant of the rapid (initial) decay
phase, respectively, and B and β were the y intercept and
decay constant of the slow decay phase, respectively [19].
2.4. Renal Morphology. Paraﬃn-embedded renal sections
(4 to 5 specimens per group) were stained with Periodic
Acid Schiﬀ (PAS) and Masson’s Trichrome staining and
visualized by light microscopy by an observer blinded
to the treatment group. The collected glomerular imagesExperimental Diabetes Research 3
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Figure 1: Physiological parameters measurement in 3 groups (control (open bar), diabetic (black bar), and insulin-treated diabetic
(shadowed bar)) of both WT and AT2RKO male mice at the age of 16 weeks. (a) Gross body weight (BW, g); (b) Food consumptions
(g/day); (c) KW/BW ratio; (d) blood glycemic concentration (mM). ∗P ≤ 0.05; ∗∗P ≤ 0.01; NS, non signiﬁcant.
were analyzed and quantiﬁed by NIH Image J software
(http://rsb.info.nih.gov/ij/)a sr e p o r t e dp r e v i o u s l y[ 20–22].
2.5. Apoptosis Assay. Apoptosis was quantiﬁed by the trans-
ferase-dUTP-nicked-end labeling (TUNEL) as reported pre-
viously [16, 23]. Semiquantitation of apoptotic cells in the
kidneys was performed as previously reported [20–22].
2.6. ROS Generation. Freshly isolated RPTs were imme-
diately processed for ROS measurement by the lucigenin
methodasdescribedpreviously[20,21,24].ROSproduction
was normalized with protein concentration and expressed as
relative light units (RLUs) per μg protein.
2.7. Real-Time-Quantitative Polymerase Chain Reaction (RT-
qPCR). Total RNA extracted from freshly isolated RPTs was
assayed for gene expression by real time quantitative PCR
(RT-qPCR) as reported previously [16, 17, 23]. Fast SYBR
Green Mastermix kit and the 7500 fast real-time PCR system
(Applied Biosystems, Life Technologies, Foster City, Calif,
USA) were employed for this purpose.
2.8. Immunohistochemistry. Immunohistochemistry (IHC)
was performed by the standard avidin-biotin-peroxidase
complexmethod (ABCStaining System,SantaCruzBiotech-
nologies, Santa Cruz, Calif, USA), as described elsewhere
[16,23].Polyclonalanti-angiotensinogen(Agt)antibodywas
a gift from Dr. John S.D. Chan (CRCHUM—Hˆ otel-Dieu
Hospital). Other antibodies, including AT1R, ACE, and anti-
heme oxygenase-1 (HO-1), were purchased from Santa Cruz
Biotechnologies. Monoclonal ACE2 antibody was procured
from R&D Systems, Inc. (Burlington, ON, Canada).
2.9. Statistical Analysis. Statistical signiﬁcance between the
experimental groups was analyzed by 1-way ANOVA, fol-
lowed by the Bonferroni test with Graphpad Software,
Prism 5.0 (http://www.graphpad.com/prism/Prism.htm). A
probability level of P ≤ 0.05 was considered to be statistically
signiﬁcant as compared with WT control animal.4 Experimental Diabetes Research
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Figure 2: (a) Longitudinal and cross-sectional changes in mean SBP in 3 subgroups (e.g., control (•), diabetic (), and insulin-treated
diabetic ()) of WT (broken line) and AT2RKO male mice (solid line) from the age of 12 to 16 weeks. (b) Mean SBP in 3 groups control
(open bar), diabetic (black bar), and insulin-treated diabetic (shadowed bar) of WT and AT2R K Om a l em i c ea tt h ea g eo f1 6w e e k s .( c )G F R
in 3 groups (control (open bar), diabetic (black bar), and insulin-treated diabetic (shadowed bar)) of WT and AT2R K Om a l em i c ea ta g e1 6
weeks. ∗P ≤ 0.05.
3. Results
3.1.PhysiologicalFindings. Wemeasuredsomebiologicalpa-
rameters such as BW (g), KW (mg), daily food consump-
tion (g/day), and blood glycemic concentration (mM) in
3 subgroups of animals (nondiabetic control, and diabetic,
with or without insulin treatment) of both WT and AT2RKO
mice. There were no signiﬁcant diﬀerences between AT2RKO
and WT mice with or without diabetes in terms of BW
(Figure 1(a)) (WT mice (g), control (N = 15), 28.9 ±
3.39; diabetic (N = 14), 25.52 ± 1.38; diabetic with insulin
treatment (N = 13), 26.07 ± 1.91; AT2RKO mice (g), control
(N = 15), 25.13 ± 1.40; diabetic (N = 15), 23.96 ±
1.25; diabetic with insulin treatment (N = 13), 24.05 ±
2.82 and daily food consumption (Figure 1(b))( W Tm i c e
(g/day), control (N = 15), 2.96 ± 0.41; diabetic (N = 14),
4.35 ± 0.77; and diabetic with insulin treatment (N = 13),
3.37 ± 0.67; AT2RKO mice (g), control (N = 15), 2.82
± 0.50; diabetic (N = 15), 4.44 ± 0.89; diabetic with
insulin treatment (N = 13), 3.45 ± 0.34). As expected,
renal hypertrophy (Figure 1(c))( d e ﬁ n e db yt h er a t i oo fK W
versus BW) was present in diabetic animals of both AT2RKO
and WT mice; insulin therapy normalized the hyperglycemia
(Figure 1(d)) (WT mice (mM), control (N = 15), 7.87 ±
1.59; diabetic (N = 14), 31.43 ± 3.68; diabetic with insulin
treatment (N = 13), 15.13 ± 4.18; AT2RKO mice (mM),
control (N = 15), 10.16 ± 0.99; diabetic (N = 15), 28.38 ±
3.6; diabetic with insulin treatment (N = 13), 12.64 ± 3.59).Experimental Diabetes Research 5
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Figure 3: Renal morphology assessed by (a) and (b) PAS staining and (c) and (d) Masson’s trichrome staining (magniﬁcation 600X). (b)
and (d) Quantiﬁcation of relatively stained arbitrary units of PAS (b) and Masson’s Trichrome (d) in 3 subgroups [control (black bar),
diabetic (red bar) and insulin-treated diabetic (blue bar)] of WT and AT2RKO male mice at the age of 16 weeks. The y-axis shows the
percentage of relative staining values compared to WT control animals (100%). (e) Renal collagen IV mRNA expression analyzed by RT-
qPCR. Quantitation of renal collagen IV gene was normalized to its own β-actin mRNA. The y-axis shows the percentage of relative values
compared to WT animals (100%). ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; NS, nonsigniﬁcant.
3.2. Mean Systolic Blood Pressure (SBP) and Glomerular
Filtration Rate (GFRs) Measurement. SBP increased over
time in AT2RKO mice as reported [8]( Figure 2(a)), and
the development of hypertension appeared independent of
diabetes(Figure 2(b)).Forexample,after4weeksofdiabetes,
there was no further increase in the SBP in either WT or
AT2RKO mice (Figure 2(b))( W Tm i c e ,c o n t r o l( N = 10),
112.5 ± 5.78mmHg; WT diabetic (N = 12), 111.40 ±
4.51mmHg; WT diabetic with insulin treatment (N = 9),
114 ± 4.27mmHg; AT2RKO mice, control (N = 13), 130.04
± 7.00mmHg; AT2RKO diabetic (N = 12), 132.20 ±
5.62mmHg; AT2RKO diabetic with insulin treatment (N =
10), 128.97 ± 1.28mmHg).
AT2RKO mice had higher GFRs [(uL/min)/BW(g)] by
FITC-inulin measurement (Figure 2(c)) (control: 42.74 ±
4.3, (N = 8); diabetic 56.10 ± 4.9, (N = 8); diabetic with
insulin treatment 37.16 ± 6.5, (N = 7)) at 16 weeks of
age as compared to WT (control: 35.33 ± 4.5, (N = 8);
diabetic 49.78 ± 5.4, (N = 9); and diabetic with insulin
treatment38.93 ± 5.56, (N = 7)).Thus,renalhyperﬁltration
occurs in AT2RKO mice, which may possibly contribute to
the development of hypertension.
3.3. Renal Morphology and Apoptosis. Extracellular matrix
(ECM) protein accumulation in glomeruli and tubular
apoptosis are the key features of diabetic nephropathy. As
compared to WT animals at the age of 16 weeks, AT2RKO
mice display increased ECM accumulation in the glomeruli
(Figures 3(a)–3(b), PAS staining) and tubulointerstitium
(Figures 3(c) and 3(d), Masson trichrome staining) with
upregulation of renal collagen IV mRNA level (Figure 3(e)),
as well as tubular apoptosis (Figure 4, TUNEL assay). These
features were further pronounced in diabetic animals and
partiallyattenuatedinthe insulin-treatedgroups inboth WT
and AT2RKO mice.
3.4. ROS Generation. Heme oxygenase 1 (HO-1) is an oxida-
tive stress-inducible enzyme that confers cellular oxidative
stress in vivo, as reported previously [25]. Compared to
WT mice at the age of 16 weeks, HO-1 expression, as seen
by IHC (Figure 5(a)) and Western blot (Figure 5(b)), was
increasedsigniﬁcantlyinRPTcellsofAT2RKOmice,andthis
increment was even more marked in diabetic and prevented
in insulin-treated AT2RKO mice.
We conﬁrmed the renal HO-1 IHC results in freshly
isolatedRPTsfromthe3subgroupsofAT2RKOandWTmice6 Experimental Diabetes Research
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Figure 4: (a) TUNEL assay (magniﬁcation 200X) in the kidneys of
3 subgroups [control (open bar), diabetic (black bar) and insulin-
treated diabetic (shadowed bar)] of WT and AT2RKO male mice
at age 16 weeks. (b) Semi-quantitation of apoptotic cells in the
kidneys.They-axisshowsthefoldincreaseofapoptoticcellnumber
in the kidneys of 3 subgroups of mice. ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001;
NS, non-signiﬁcant.
by measuring ROS generation according to the lucigenin
method [20, 21, 24]. Compared to WT animals, ROS gen-
eration was signiﬁcantly augmented in freshly isolated RPTs
from AT2RKO mice (Figure 5(c)), and this ROS elevation
was even more striking in diabetic and attenuated in insulin-
treated AT2RKO mice (Figure 5(c)). Moreover, as compared
with control WT mice, p47phox mRNA (one of NADPH
oxidase components) seems to be upregulated in RPTs of
AT2RKO mice, and this upregulation appears to be more
profound in diabetic condition (Figure 5(d)).
3.5. Activation of Intrarenal RAS. First, we assessed the basal
expression of several key components of the RAS—Agt,
AT1R, ACE, and ACE2—by RT-qPCR and Western blotting
in freshly isolated RPTs from both WT and AT2RKO mice.
Compared to WT animals, the intrarenal RAS genes, that is,
Agt,AT1R,andACE,wereincreased,butACE2wasdecreased
in RPTs of AT2RKO mice (Figure 6).
To establish a linkage between nephropathy development
and intrarenal RAS activation in diabetes more completely,
we evaluated intrarenal RAS genes by IHC in the kidneys of
3 subgroups of animals from both AT2RKO and WT mice.
As compared to WT mice, the enhanced Agt, AT1R, and
ACE were more striking in the diabetic kidneys of AT2RKO.
For example, the elevation of Agt protein expression was
mainly localized in the proximal tubules (Figures 7(a) and
7(b)). AT1R were detected in the proximal tubules and small
intrarenal vessels (Figures 7(c) and 7(d)) with ACE on the
luminal side of the proximal tubules (Figures 8(a) and 8(b)).
The increased Agt, AT1R, and ACE expression appeared to
be partially ameliorated in the kidneys of insulin-treated
animals (Figure 7 and Figure 8).
In contrast, ACE2 gene expression was signiﬁcantly
downregulated in RPTs of AT2RKO mice (Figure 6).
Although its expression was similar in location to that of
ACE, ACE2 was signiﬁcantly decreased in RPTs of AT2RKO
mice, but was relatively increased in diabetic kidneys of
AT2RKO mice (Figures 8(c) and 8(d)), consistent with
previously reported counterregulatory interactions between
ACE and ACE2, which may play a role in hypertension in
diabetes [13, 14, 26].
4. Discussion
The present study examined potential mechanisms of the
functional role(s) of AT2R deﬁciency in the development of
nephropathy in type I diabetes. AT2R deﬁciency accelerated
the development of DN, which appears to be mediated, at
least in part, via elevated oxidative stress and ACE/ACE2
ratio in RPTs.
In contrast to the well-established functional impact of
AT1R in DN, few data are currently available concerning
the role of the AT2R in diabetes and DN progression. It has
been postulated that the action of AT2R may counterbalance
the action of AT1R in hypertension and kidney disease.
For instance, activation of the AT2R leads to vasodilatation
[27] (e.g., possibly via activation of bradykinin-cGMP-nitric
oxide (NO) pathway [28] and suppression of renin biosyn-
thesisandreleasefromrenaljuxtaglomerularcells[28];these
lead to vasodilatation and natriuresis, which then reduces
blood pressure), mediates natriuresis (e.g., possibly via the
renal dopaminergic system, a crucial system in the control
of renal sodium excretion and blood pressure) [29], and
causesantiproliferative/proapoptotic responses[30].Thus,it
seems reasonable that AT2R might have a counterregulatory
role opposing AT1R-mediated vasoconstriction, but such
mechanistic conclusions are based mainly on the studies in
which an antagonist of AT2R, PD123319, was used to block
AT2Rf u n c t i o n[ 29]. In this regard, a model in which AT2R
is ablated, such as AT2RKO mice, has been eagerly used to
determinewhetheractivationoftheAT2Risimportantinthe
progression of diabetic nephropathy. If so, manipulating the
AT2R could act as a potential therapeutic strategy in DN.
Our studies conﬁrmed observations that, as compared to
WT animals, AT2RKO enhanced renal ﬁbrosis [31]. After 4
weeks of diabetes, AT2RKO develops clear evidence of DN,
showing renal hypertrophy, tubular apoptosis, and progres-
sive accumulation of glomerular and tubulointerstitial ECMExperimental Diabetes Research 7
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Figure 5:(a)HO-1IHCstaining(magniﬁcation200X)inthekidneysof3subgroups(control,diabetic,andinsulin-treateddiabetic)ofboth
WT and AT2RKO male mice. (b) HO-1 expression analyzed by Western blot in freshly isolated RPTs from 3 subgroups (control (open bar),
diabetic (black bar), and insulin-treated diabetic (shadowed bar)) of WT and AT2RKO male mice. The quantitation of the relative densities
of HO-1 normalized to β-actin. The y-axis shows the percentage of relative values compared to WT controls (100%). ∗∗P ≤ 0.01; (c) ROS
measurement in RPTs. The y-axis shows relative ROS production values compared to WT controls (100%). (d) p47phox mRNA expression
in RPTs analyzed by RT-qPCR. Quantitation of p47phox gene was normalized to its own β-actin mRNA. The y-axis shows the percentage of
relative values compared to WT animals (100%). ∗P ≤ 0.05. ∗∗P ≤ 0.01; NS, nonsigniﬁcant.
proteins as well as increased GFR, suggesting that deﬁciency
ofAT2RmightacceleratetheprogressofdevelopmentofDN.
There are several possible mechanisms by which deﬁ-
ciency of AT2R accelerates the development of DN. First,
renal hyperﬁltration (a key component causing endothelial
dysfunction and mesangial stretch) with increased GFR is a
hallmark of early DN [32]. As compared with WT animals,
there was pronounced hyperﬁltration in AT2RKO mice in
diabetes; we speculate that this apparent hyperﬁltration
contributes to the development of hypertension and DN
observed in AT2RKO mice—with or without diabetes.
However, our data contrast with the report by Sourris et
al. [33] who claimed that lower GFRs were seen in diabetic
AT2RKO mice. These disparate results could be explained
by technical diﬀerences in how the studies were performed:
(1) we directly measured the GFR, and the other group
of authors used urinary albumin excretion rates (AER)
and creatinine clearance to estimate GFR; (2) our animals
were diabetic for four weeks, whereas theirs had diabetes
for 24 weeks. Thus, the stage of DN was not comparable.8 Experimental Diabetes Research
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(b) Basal protein expression in RPT by western blot.
Figure 6: Basal expression of intrarenal RAS genes (i.e., Agt, AT1R, ACE, and ACE2) in freshly isolated RPTs from WT (open bar) and
AT2RKO (black bar) male mice at the age of 16 weeks. (a) RT-qPCR. Quantitation of relative intra-renal RAS genes was normalized to their
own β-actin mRNA. The y-axis shows the percentage of relative values compared to WT animals (100%). ∗P ≤ 0.05. (b) Western blotting.
Quantitation of relative densities of intrarenal RAS genes was normalized to β-actin. The y-axis shows the percentage of relative values
compared to WT animals (100%). ∗∗P ≤ 0.01.
Jerums et al. [32] recently reviewed the assessments of AER
and GFR in diabetic nephropathy, indicating that changes
in AER are dynamic, whereas changes in GFR are usually
progressive; additionally increases in AER generally, precede
a decline in GFR [32].
Second, R¨ uster et al. [34] indicated that Ang II via AT2R
in podocytes upregulates RAGE (receptors for AGEs) pro-
duction, the key pathogenic factor in diabetic renal injury.
Recently, Sourris et al. [33] reported that overexpression of
RAGE in primary mesangial cell cultures via an adenovector-
based construct enhanced superoxide generation with a sig-
niﬁcant decline of AT2R expression; AT2RKO mice exhibited
signiﬁcantly higher renal superoxide production in freshly
minced kidney cortex as compared with those from WT
animals; however, elevated renal superoxide production in
the AT2RKO remained unaﬀected by diabetes. Then, they
postulated that the pathogenic interactions among the
RAGE, AT2R deﬁciency, and ROS generation might impact
the development of diabetic renal injury.
Previously, we demonstrated that intrarenal RAS acti-
vation and high glucose via ROS generation may act in
concert to increase proximal tubular cell (RPTs) apoptosis
and tubulointerstitial ﬁbrosis in diabetes, independent of
systemic hypertension [16, 17]. In the current study, we
observed that ROS generation in the renal cortex was
signiﬁcantly augmented in RPTs of AT2RKO mice as assessed
by HO-1 expression, and we validated our observation in
freshly isolated RPTs from AT2RKO mice. This elevation of
ROS was even more pronounced in the kidneys of diabetic
AT2RKO mice and attenuated in the insulin-treated animals.
NADPH oxidase plays an important role in the ROS
generation in DN. NADPH oxidase consists of severalExperimental Diabetes Research 9
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Figure 7: IHC staining of mAgt (a) and (b) and AT1R (c) and (d) genes. (a) and (c) IHC images of Agt and AT1R in the kidneys of 3
subgroups of both WT and AT2RKO male mice (magniﬁcation 600X). (b) and (d) Semiquantiﬁcation of IHC expression in the kidneys of 3
subgroups (control (black bar), diabetic (red bar), and insulin-treated diabetic (blue bar)) of WT and AT2RKO male mice. The y-axis shows
the percentage of relative staining values compared to WT control animals (100%). ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001.
membrane-bound subunits (gp91phox, nox, and p22phox)
and cytosolic subunits (p47phox and p67phox). It has been
reported that oxidative stress in the diabetic nephropathy is
mediated, at least in part, through p47phox activation [35,
36]. By qPCR analysis, we have found that as compared with
control WT mice, p47phox mRNA seems to be upregulated
inRPTsofAT2RKOmice,andthisupregulationappearstobe
more profound in diabetic condition. Taken together, these
datasuggestedthatAT2RdeﬁciencyincreasedintrarenalROS
generation in RPTs, leading to acceleration of the progress of
DN.
Third, while functional linkage of ACE2-Ang-(1-7)-Mas
axis and oxidative stress is evident in the heart [37], the
role of ACE2 expression and high glucose/Ang II-induced
ROS generation in kidney pathophysiology is still not estab-
lished [37–39]. To date, evidence indicates that recombinant
human ACE2 prevents Ang II-induced hypertension, renal
oxidative stress, and tubulointerstitial ﬁbrosis [40] while
attenuating diabetic kidney injury in Akita mice in associ-
ation with reduced blood pressure and decreased NADPH
oxidase activity [41]. Since AT2R inhibits ACE activity [15],
which may, in part, underlie AT2R increasingly recognized10 Experimental Diabetes Research
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Figure 8: IHC staining of ACE (a) and (b) and ACE2 (c) and (d) genes. (a) and (c) IHC images of ACE and ACE2 in the kidneys of 3
subgroups of WT and AT2RKO male mice (magniﬁcation 200X). (b) and (d) Semiquantiﬁcation of IHC expression in the kidneys of 3
subgroups (control (black bar), diabetic (red bar), and insulin-treated diabetic (blue bar)) of WT and AT2RKO male mice. The y-axis shows
the percentage of relative staining values compared to WT controls (100%). ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001.
attenuationofAT1R-mediatedactions,ontheotherhand,we
speculate that AT2R might increase ACE2 activity and then
decrease the ACE/ACE2 ratio to prevent the diabetic renal
injury. Our data from this study further tested and support
this hypothesis in an in vivo model.
The key components of the intrarenal RAS, including
Agt, AT1R, and ACE are signiﬁcantly upregulated, whereas
ACE2 is downregulated, in renal proximal tubules of
AT2RKO mice compared to WT animals. Additionally, the
elevation of AT1R, as seen in small intrarenal vessels, also
favors the development of DN. Moreover, the increased
classic RAS gene expression (i.e., Agt, AT1R, and ACE)
was further enhanced in diabetic AT2RKO mice, and that
expression is particularly attenuated in the kidneys of
insulin-treated animals. Taken together, these data suggest
that intratubular Ang II is increased in proximal tubules of
AT2RKO with or without diabetes; the increased ACE/ACE2
ratio might accelerate, at least in part, favoring the develop-
ment of DN.
In summary, our results suggest that deﬁciency of AT2R
that enhanced or accelerated the development of diabetic
nephropathy is mediated, at least in part, via elevated ROS
generation and activation of intrarenal RAS genes with
downregulation of ACE2 gene expression in RPTs.
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